Conor M Lane1, John R Giudicessi2, Dan Ye1, David J Tester1, Ram K Rohatgi3, J Martijn Bos1, Michael J Ackerman4. 1. Departments of Cardiovascular Medicine, Division of Heart Rhythm Services, Pediatric and Adolescent Medicine, Division of Pediatric Cardiology, and Molecular Pharmacology & Experimental Therapeutics, Windland Smith Rice Sudden Death Genomics Laboratory, Mayo Clinic, Rochester, Minnesota. 2. Departments of Cardiovascular Medicine and Internal Medicine (Clinician-Investigator Training Program), Mayo Clinic, Rochester, Minnesota. 3. Department of Pediatric and Adolescent Medicine, Division of Pediatric Cardiology, Mayo Clinic, Rochester, Minnesota. 4. Departments of Cardiovascular Medicine, Division of Heart Rhythm Services, Pediatric and Adolescent Medicine, Division of Pediatric Cardiology, and Molecular Pharmacology & Experimental Therapeutics, Windland Smith Rice Sudden Death Genomics Laboratory, Mayo Clinic, Rochester, Minnesota. Electronic address: ackerman.michael@mayo.edu.
Abstract
BACKGROUND: Long QT syndrome (LQTS) genetic test reports commonly exclude potentially proarrhythmic common variants such as p.Asp85Asn-KCNE1. OBJECTIVE: The purpose of this study was to determine whether a discernible phenotype is associated with p.Asp85Asn-KCNE1 and whether relatively common KCNE1 variants underlie transient QT prolongation pedigrees with negative commercial LQTS genetic tests. METHODS: Retrospective review was used to compare demographics, symptomatology, and QT parameters of individuals with p.Asp85Asn-KCNE1 in the absence of other rare/ultra-rare variants in LQTS-susceptibility genes and those who underwent comprehensive LQTS genetic testing. RESULTS: Compared to the Genome Aggregation Database, p.Asp85Asn-KCNE1 was more prevalent in individuals undergoing LQTS genetic testing (33/1248 [2.6%] vs 1552/126,652 [1.2%]; P = .0001). In 19 of 33 patients (58%), only p.Asp85Asn-KCNE1 was observed. These patients were predominantly female (90% vs 62%; P = .01) and were less likely to experience syncope (0% vs 34%; P = .0007), receive β-blockers (53% vs 85%; P = .001), or require an implantable cardioverter-defibrillator (5.3% vs 33%; P = .01). However, they exhibited a similar degree of QT prolongation (QTc 460 ms vs 467 ms; P = NS). Whole exome sequencing of 2 commercially genotype-negative pedigrees revealed that p.Asp85Asn-KCNE1 and p.Arg36His-KCNE1 traced with a transient QT prolongation phenotype. Functional characterization of p.Arg36His-KCNE1 demonstrated loss of function, with a 47% reduction in peak IKs current density in the heterozygous state. CONCLUSION: We provide further evidence that relatively common variants in KCNE1 may result in a mild QT phenotype designated as "LQT5-Lite" to distinguish such potentially proarrhythmic common variants (ie, functional risk alleles) from rare pathogenic variants that truly confer monogenic disease susceptibility, albeit with incomplete penetrance.
BACKGROUND:Long QT syndrome (LQTS) genetic test reports commonly exclude potentially proarrhythmic common variants such as p.Asp85Asn-KCNE1. OBJECTIVE: The purpose of this study was to determine whether a discernible phenotype is associated with p.Asp85Asn-KCNE1 and whether relatively common KCNE1 variants underlie transient QT prolongation pedigrees with negative commercial LQTS genetic tests. METHODS: Retrospective review was used to compare demographics, symptomatology, and QT parameters of individuals with p.Asp85Asn-KCNE1 in the absence of other rare/ultra-rare variants in LQTS-susceptibility genes and those who underwent comprehensive LQTS genetic testing. RESULTS: Compared to the Genome Aggregation Database, p.Asp85Asn-KCNE1 was more prevalent in individuals undergoing LQTS genetic testing (33/1248 [2.6%] vs 1552/126,652 [1.2%]; P = .0001). In 19 of 33 patients (58%), only p.Asp85Asn-KCNE1 was observed. These patients were predominantly female (90% vs 62%; P = .01) and were less likely to experience syncope (0% vs 34%; P = .0007), receive β-blockers (53% vs 85%; P = .001), or require an implantable cardioverter-defibrillator (5.3% vs 33%; P = .01). However, they exhibited a similar degree of QT prolongation (QTc 460 ms vs 467 ms; P = NS). Whole exome sequencing of 2 commercially genotype-negative pedigrees revealed that p.Asp85Asn-KCNE1 and p.Arg36His-KCNE1 traced with a transient QT prolongation phenotype. Functional characterization of p.Arg36His-KCNE1 demonstrated loss of function, with a 47% reduction in peak IKs current density in the heterozygous state. CONCLUSION: We provide further evidence that relatively common variants in KCNE1 may result in a mild QT phenotype designated as "LQT5-Lite" to distinguish such potentially proarrhythmic common variants (ie, functional risk alleles) from rare pathogenic variants that truly confer monogenic disease susceptibility, albeit with incomplete penetrance.
Authors: Marta Tomás; Carlo Napolitano; Luciana De Giuli; Raffaella Bloise; Isaac Subirana; Alberto Malovini; Riccardo Bellazzi; Dan E Arking; Eduardo Marban; Aravinda Chakravarti; Peter M Spooner; Silvia G Priori Journal: J Am Coll Cardiol Date: 2010-06-15 Impact factor: 24.094
Authors: Peter A Noseworthy; Aki S Havulinna; Kimmo Porthan; Annukka M Lahtinen; Antti Jula; Pekka J Karhunen; Markus Perola; Lasse Oikarinen; Kimmo K Kontula; Veikko Salomaa; Christopher Newton-Cheh Journal: Circ Cardiovasc Genet Date: 2011-04-21
Authors: L Gouas; V Nicaud; S Chaouch; M Berthet; A Forhan; J Tichet; L Tiret; B Balkau; P Guicheney Journal: Eur J Hum Genet Date: 2007-05-30 Impact factor: 4.246
Authors: Michael J Ackerman; Igor Splawski; Jonathan C Makielski; David J Tester; Melissa L Will; Katherine W Timothy; Mark T Keating; Gregg Jones; Monica Chadha; Christopher R Burrow; J Claiborne Stephens; Chuanbo Xu; Richard Judson; Mark E Curran Journal: Heart Rhythm Date: 2004-11 Impact factor: 6.343
Authors: Michael J Ackerman; David J Tester; Gregg S Jones; Melissa L Will; Christopher R Burrow; Mark E Curran Journal: Mayo Clin Proc Date: 2003-12 Impact factor: 7.616
Authors: Lia Crotti; Maria Cristina Monti; Roberto Insolia; Anna Peljto; Althea Goosen; Paul A Brink; David A Greenberg; Peter J Schwartz; Alfred L George Journal: Circulation Date: 2009-10-12 Impact factor: 29.690
Authors: A Marjamaa; C Newton-Cheh; K Porthan; A Reunanen; P Lahermo; H Väänänen; A Jula; H Karanko; H Swan; L Toivonen; M S Nieminen; M Viitasalo; L Peltonen; L Oikarinen; A Palotie; K Kontula; V Salomaa Journal: J Intern Med Date: 2009-10-25 Impact factor: 8.989
Authors: Jason D Roberts; S Yukiko Asaki; Andrea Mazzanti; J Martijn Bos; Izabela Tuleta; Alison R Muir; Lia Crotti; Andrew D Krahn; Valentina Kutyifa; M Benjamin Shoemaker; Christopher L Johnsrude; Takeshi Aiba; Luciana Marcondes; Anwar Baban; Sharmila Udupa; Brynn Dechert; Peter Fischbach; Linda M Knight; Eric Vittinghoff; Deni Kukavica; Birgit Stallmeyer; John R Giudicessi; Carla Spazzolini; Keiko Shimamoto; Rafik Tadros; Julia Cadrin-Tourigny; Henry J Duff; Christopher S Simpson; Thomas M Roston; Yanushi D Wijeyeratne; Imane El Hajjaji; Maisoon D Yousif; Lorne J Gula; Peter Leong-Sit; Nikhil Chavali; Andrew P Landstrom; Gregory M Marcus; Sven Dittmann; Arthur A M Wilde; Elijah R Behr; Jacob Tfelt-Hansen; Melvin M Scheinman; Marco V Perez; Juan Pablo Kaski; Robert M Gow; Fabrizio Drago; Peter F Aziz; Dominic J Abrams; Michael H Gollob; Jonathan R Skinner; Wataru Shimizu; Elizabeth S Kaufman; Dan M Roden; Wojciech Zareba; Peter J Schwartz; Eric Schulze-Bahr; Susan P Etheridge; Silvia G Priori; Michael J Ackerman Journal: Circulation Date: 2020-01-16 Impact factor: 29.690
Authors: Thomas M Roston; Omid Haji-Ghassemi; Martin J LaPage; Anjan S Batra; Yaniv Bar-Cohen; Chris Anderson; Yung R Lau; Kathleen Maginot; Roman A Gebauer; Susan P Etheridge; James E Potts; Filip Van Petegem; Shubhayan Sanatani Journal: PLoS One Date: 2018-11-07 Impact factor: 3.240
Authors: Krystian Kozek; Yuko Wada; Luca Sala; Isabelle Denjoy; Christian Egly; Matthew J O'Neill; Takeshi Aiba; Wataru Shimizu; Naomasa Makita; Taisuke Ishikawa; Lia Crotti; Carla Spazzolini; Maria-Christina Kotta; Federica Dagradi; Silvia Castelletti; Matteo Pedrazzini; Massimiliano Gnecchi; Antoine Leenhardt; Joe-Elie Salem; Seiko Ohno; Yi Zuo; Andrew M Glazer; Jonathan D Mosley; Dan M Roden; Bjorn C Knollmann; Jeffrey D Blume; Fabrice Extramiana; Peter J Schwartz; Minoru Horie; Brett M Kroncke Journal: Circ Genom Precis Med Date: 2021-07-26